<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664023</url>
  </required_header>
  <id_info>
    <org_study_id>BIOMARK-COVID</org_study_id>
    <nct_id>NCT04664023</nct_id>
  </id_info>
  <brief_title>Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution</brief_title>
  <acronym>BIOMARK-COVID</acronym>
  <official_title>Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 and Its Resolution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective study to describe the immunological, metabolic and serologic profile in the acute&#xD;
      and post acute phases of Coronavirus disease (COVID-19)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neutralizing antibodies</measure>
    <time_frame>Day 8 following the first SARS-CoV-2 symptoms</time_frame>
    <description>Serum titre of neutralizing antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T CD8 lymphocytes</measure>
    <time_frame>Day 8 following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood concentration of T CD8 lymphocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Day 8 following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood levels of pro-inflammatory cytokines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic markers</measure>
    <time_frame>Day 8 following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood concentration of glucosidases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibodies</measure>
    <time_frame>Day 16 following the first SARS-CoV-2 symptoms</time_frame>
    <description>Serum titre of neutralizing antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T CD8 lymphocytes</measure>
    <time_frame>Day 16 following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood concentration of T CD8 lymphocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Day 16 following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood levels of pro-inflammatory cytokines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic markers</measure>
    <time_frame>Day 16 following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood concentration of glucosidases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibodies</measure>
    <time_frame>Day 24 following the first SARS-CoV-2 symptoms</time_frame>
    <description>Serum titre of neutralizing antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T CD8 lymphocytes</measure>
    <time_frame>Day 24 following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood concentration of T CD8 lymphocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Day 24 following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood levels of pro-inflammatory cytokines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic markers</measure>
    <time_frame>Day 24 following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood concentration of glucosidases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibodies</measure>
    <time_frame>6 months following the first SARS-CoV-2 symptoms</time_frame>
    <description>Serum titre of neutralizing antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T CD8 lymphocytes</measure>
    <time_frame>6 months following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood concentration of T CD8 lymphocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>6 months following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood levels of pro-inflammatory cytokines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic markers</measure>
    <time_frame>6 months following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood concentration of glucosidases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibodies</measure>
    <time_frame>12 months following the first SARS-CoV-2 symptoms</time_frame>
    <description>Serum titre of neutralizing antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T CD8 lymphocytes</measure>
    <time_frame>12 months following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood concentration of T CD8 lymphocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>12 months following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood levels of pro-inflammatory cytokines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic markers</measure>
    <time_frame>12 months following the first SARS-CoV-2 symptoms</time_frame>
    <description>Blood concentration of glucosidases</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Patients with severe SARS-CoV-2 infection</arm_group_label>
    <description>Patients with severe SARS-CoV-2 infection hospitalised in intensive care unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with intermediate SARS-CoV-2 infection</arm_group_label>
    <description>Patients with intermediate SARS-CoV-2 infection hospitalised in infectious and tropical diseases department</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Little symptomatic patients with SARS-CoV-2 infection</arm_group_label>
    <description>Little symptomatic ambulatory patients with SARS-CoV-2 infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with SARS-CoV-2 infection hospitalised in geriatry department</arm_group_label>
    <description>Patients with SARS-CoV-2 infection hospitalised in geriatry department to study influence of age on the studied mechanisms</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection</intervention_name>
    <description>40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis</description>
    <arm_group_label>Little symptomatic patients with SARS-CoV-2 infection</arm_group_label>
    <arm_group_label>Patients with SARS-CoV-2 infection hospitalised in geriatry department</arm_group_label>
    <arm_group_label>Patients with intermediate SARS-CoV-2 infection</arm_group_label>
    <arm_group_label>Patients with severe SARS-CoV-2 infection</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from&#xD;
      SARS-CoV-2 infection 40mL blood sample will be collected at each blood collection.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe SARS-CoV-2 infection hospitalised in intensive care unit&#xD;
&#xD;
        Patients with intermediate SARS-CoV-2 infection hospitalised in infectious and tropical&#xD;
        diseases department&#xD;
&#xD;
        Little symptomatic ambulatory patients with SARS-CoV-2 infection&#xD;
&#xD;
        Patients with SARS-CoV-2 infection hospitalised in geriatry department&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patient&#xD;
&#xD;
          -  Patient with Covid-19 confirmed by RT-PCR, supported by Poitiers hospital&#xD;
&#xD;
          -  Patient came for RT-PCR test at the drive of the hospital, or hospitalised in one of&#xD;
             the Covid-19 departments of the Poitiers hospital (geriatry, infectious and tropical&#xD;
             diseases, medical resuscitation and continuous care unit)&#xD;
&#xD;
          -  informed consent signed by the patient or a trusted or immediate person after clear&#xD;
             and loyal information on the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  minor patient&#xD;
&#xD;
          -  patient having had syptoms for more than 8 days&#xD;
&#xD;
          -  patient already enrolled in another study regarding immunomodulators&#xD;
&#xD;
          -  patient not benefiting from a Social Security scheme or not benefiting from it through&#xD;
             a third party&#xD;
&#xD;
          -  patient benefiting from enhanced protection, namely minors, persons deprived of their&#xD;
             liberty by a judicial or administrative decision, adult under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas Lévêque, MD</last_name>
    <phone>+33 5.49.44.38.17</phone>
    <email>nicolas.leveque@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>C.H.U.de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Lévêque, MD</last_name>
      <phone>+33549443817</phone>
      <email>nicolas.leveque@chu-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Immunologic biomarkers</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

